Scilex Holding Co
No enriched coverage for $SCLX in the last 7 days.
No SEC Form 4 filings for $SCLX in the last 30 days.
See all $SCLX insider activity →Scilex Holding Co (SCLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2026 (the “Effective Date”), Scilex Holding Company (the “Company”) entered into a Promissory Note (Revolving Line of Credit) (the “Note”) with Vivasor, Inc. (“Vivasor”), as borrower, pursuant to which the Compan
Scilex Holding Co (SCLX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 sclx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Stock repurchase AGREEMENT This Stock Repurchase Agreement (this “ Agreement ”) is made and entered into effective as of July 18, 2026 (the “ Effective Date ”) by and among (i) Vivasor Holding Company, a Delaware corporation
Scilex Holding (NASDAQ:SCLX) shares rose about 7% after it said it signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based iHolding Group LLP. iHolding would buy ~6.7 million newly issued shares at $15.00 each. The funding would support expansion, product development, commercialization, acquisitions, and working capital; the deal is subject to closing conditions and approvals.
Recent SCLX coverage spans corporate actions, mergers & acquisitions and crypto.
The 8-K adds financing optionality via an uncommitted revolving note, but it is not a guaranteed funding event.
The filing indicates SCLX is repurchasing its preferred shares from Vivasor entities, with consideration paid partly in DVLT shares across multiple tranches.
A binding term sheet for a $100M equity investment is a near-term capital-structure catalyst, but closing is still conditional.
Token listing is a liquidity/distribution event for Scilex-linked meme tokens, but the release provides no direct financial metrics or guidance impact.
Binding term sheet for a $100M strategic investment is a fresh capital/financing catalyst that can re-rate near-term risk and liquidity expectations.
alphai scores every news story that mentions SCLX with an AI model for sentiment and relevance, and aggregates insider trades from Scilex Holding Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Scilex Holding Co (SCLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2026 (the “Effective Date”), Scilex Holding Company (the “Company”) entered into a Promissory Note (Revolving Line of Credit) (the “Note”) with Vivasor, Inc. (“Vivasor”), as borrower, pursuant to which the Compan
3 min readScilex Holding Co (SCLX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 sclx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Stock repurchase AGREEMENT This Stock Repurchase Agreement (this “ Agreement ”) is made and entered into effective as of July 18, 2026 (the “ Effective Date ”) by and among (i) Vivasor Holding Company, a Delaware corporation
4 min readScilex Holding (NASDAQ:SCLX) shares rose about 7% after it said it signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based iHolding Group LLP. iHolding would buy ~6.7 million newly issued shares at $15.00 each. The funding would support expansion, product development, commercialization, acquisitions, and working capital; the deal is subject to closing conditions and approvals.
3 min readScilex Holding Company (Nasdaq: SCLX) said Dream Bowl I Meme Coin tokens began trading on the Biconomy Exchange on July 6, 2026. The company reported it holds about 180 million Dream Bowl Tokens after the April 30, 2026 record-date distribution to eligible holders. Scilex expects trading to improve liquidity and distribution.
2 min readU.S. stock index futures rose premarket as investors returned from a holiday. Scilex Holding gained 7% on a binding term sheet for a proposed $100M strategic investment. Vera Therapeutics rose 6% ahead of a July 7 FDA PDUFA decision for atacicept. Solaris Energy Infrastructure rose 3.9% after Wolfe Research coverage and a ~$55M acquisition. Strategy rose 3.4% after adopting a framework to selectively monetize up to $1.25B in Bitcoin holdings.
4 min readScilex Holding (NASDAQ:SCLX) shares rose after the company announced a binding term sheet for a proposed $100M strategic investment from iHolding Group LLP. iHolding would buy newly issued SCLX shares at $15.00 per share (~6.7M shares). The deal is subject to due diligence, definitive agreements, approvals, and regulatory/stockholder consent.
4 min readScilex Holding Company (Nasdaq: SCLX) said it signed a binding term sheet for iHolding Group LLP to invest $100 million by purchasing newly issued Scilex shares at $15.00 per share (~6.67 million shares). Proceeds would support growth, product development, commercialization, acquisitions, working capital, and IP. Closing depends on due diligence, definitive agreements, board and stockholder approvals, and regulatory approvals.
3 min readScilex Holding Co (SCLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001820190 0001820190 2026-07-03 2026-07-03 0001820190 sclx:CommonStockParValue00001PerShare2Member 2026-07-03 2026-07-03 0001820190 sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf40250PerShareMember 2026-07-03 2026-07-03 UNITED STATES SECURITIES AND
4 min readScilex Holding Co (SCLX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001820190 false 0001820190 sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf40250PerShareMember 2026-06-24 2026-06-24 0001820190 sclx:CommonStockParValue00001PerShare2Member 2026-06-24 2026-06-24 0001820190 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND
4 min readOramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.
6 min read
